Abstract
Purpose :
To determine if there is a difference in Best Corrected Visual Acuity (BCVA) in patients with VMT in one eye and a FTMH in the other. The eye with the FTMH received PPV while that with traction only, without a FTMH, received ocriplasmin.
Methods :
Nine patients received a single injection of 0.125mg ocriplasmin (for traction alone) or PPV (for FTMH) to initially treat this condition. After the first eye was treated, with one of the two treatment options and was stable, the second eye was treated with the opposite modality. The interval between treatments averaged 4.6 months. All patients were female with ages ranging from 60 to 78 years. Three eyes were phakic OU and 6 eyes were pseudophakic OU. There were two different study sites and two surgeons (VG, AK) who performed the PPV and administered the injections. BCVA was measured at baseline (BL), 3 months, 6 months and in some patients up to two years. The mean follow up was 14 months. The order of treatment was not randomized. The eye with the worst BCVA at BL was treated first. Seven patients had PPV first while two patients had ocriplasmin as the initial treatment.
Results :
Patients in both groups had successful anatomical resolution. None of the ocriplasmin patients required subsequent PPV for VMT release. Patients who received ocriplasmin had a mean BCVA at BL of 20/61 and a final visual acuity of 20/34. In the PPV group the mean BL visual acuity was 20/156 and at study end it was 20/53. There were no statistical differences in final BCVA between these two groups. There were no differences with respect to lens status or patient age. There were no sex differences since all were female.
Conclusions :
Patients with VMT in one eye and a history of FTMH in the fellow eye who underwent PPV for FTMH benefit from early ocriplasmin treatment and could avoid the development of a FTMH in the other eye and thus a second PPV.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.